# Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

> **NCT06218914** · PHASE1 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 108 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Colorectal Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Endometrial Cancer
- Solid Tumor, Adult
- KRAS G12D

## Interventions

- **BIOLOGICAL:** NT-112: Autologous, engineered T Cells targeting KRAS G12D
- **BIOLOGICAL:** AZD0240: Autologous, engineered T Cells targeting KRAS G12D

## Key facts

- **NCT ID:** NCT06218914
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-22
- **Primary completion:** 2027-08-30
- **Final completion:** 2043-11-18
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06218914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06218914, "Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06218914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*